Clinical Trial Update: Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

A Phase 4, multicenter HR-pQCT study updates on subcutaneous tocilizumab for treating bone erosions in rheumatoid arthritis; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Centre Hospitalier Régional d'Orléans | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED